A SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY VALUES IN PATIENTS WITH HEPATITIS C VIRUS WITH AND WITHOUT SUSTAINED VIROLOGIC RESPONSE
Author(s)
Barinder Singh, RPh1, Shubhram Pandey, MSc1, Gagandeep Kaur, MPharm1, Sumeet Attri, MS1, Marvin Rock, MPH, DrPH2, Chong H Kim, MPH, MS, PhD2.
1Pharmacoevidence Private Limited, Mohali, India, 2Gilead Sciences Inc., Foster City, CA, USA.
1Pharmacoevidence Private Limited, Mohali, India, 2Gilead Sciences Inc., Foster City, CA, USA.
OBJECTIVES: Chronic hepatitis C virus (HCV) infection remains a major cause of liver-related morbidity. In patients with HCV, attaining sustained virologic response (SVR) by using direct-acting antivirals (DAAs) is a key treatment goal. The impact of SVR on health-related quality of life (HRQoL) and health utility values (HUVs) in treatment responders compared with nonresponders is not fully understood.
METHODS: The Embase and PubMed biomedical databases were searched up to April 2025. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and employed a standard 2-reviewer process for study selection and data extraction. Findings were synthesized qualitatively. Search terms in studies with adult populations (≥18 years) included viral hepatitis, QoL, utility, HRQoL, and HUV.
RESULTS: A total of 1551 citations were screened, of which 120 studies investigated the relationship between treatment response and HRQoL and/or HUVs. Of these, 78 were journal articles and 42 were conference abstracts. Most studies focused on determining HRQoL (n = 143) and/or HUVs (n = 29); study size ranged from 8 to 10,298 patients. In most studies, patients who attained SVR also had improved HRQoL scores. Attaining SVR was associated with improvement in patient-reported outcomes, whereas nonresponders showed greater deterioration, especially in mental health, social well-being, and bodily pain subscales of the 36-Item Short Form Health Survey (SF-36). Patients who attained SVR reported Health Utilities Index mean scores ranging from 0.70 to 0.80, while scores for nonresponders ranged from 0.58 to 0.74. EuroQol (EQ)-5D mean scores ranged from 0.77 to 0.97 for patients who achieved SVR and 0.87 to 0.91 for nonresponders.
CONCLUSIONS: Patients with HCV who attained SVR reported better HRQoL outcomes compared with nonresponders, specifically in mental health, social well-being, and bodily pain. Evaluating the impact of SVR on patient reported outcomes remains important for improving clinical care and supporting patient-centred decision making.
METHODS: The Embase and PubMed biomedical databases were searched up to April 2025. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and employed a standard 2-reviewer process for study selection and data extraction. Findings were synthesized qualitatively. Search terms in studies with adult populations (≥18 years) included viral hepatitis, QoL, utility, HRQoL, and HUV.
RESULTS: A total of 1551 citations were screened, of which 120 studies investigated the relationship between treatment response and HRQoL and/or HUVs. Of these, 78 were journal articles and 42 were conference abstracts. Most studies focused on determining HRQoL (n = 143) and/or HUVs (n = 29); study size ranged from 8 to 10,298 patients. In most studies, patients who attained SVR also had improved HRQoL scores. Attaining SVR was associated with improvement in patient-reported outcomes, whereas nonresponders showed greater deterioration, especially in mental health, social well-being, and bodily pain subscales of the 36-Item Short Form Health Survey (SF-36). Patients who attained SVR reported Health Utilities Index mean scores ranging from 0.70 to 0.80, while scores for nonresponders ranged from 0.58 to 0.74. EuroQol (EQ)-5D mean scores ranged from 0.77 to 0.97 for patients who achieved SVR and 0.87 to 0.91 for nonresponders.
CONCLUSIONS: Patients with HCV who attained SVR reported better HRQoL outcomes compared with nonresponders, specifically in mental health, social well-being, and bodily pain. Evaluating the impact of SVR on patient reported outcomes remains important for improving clinical care and supporting patient-centred decision making.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR115
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Infectious Disease (non-vaccine)